No abstract

BackgroundAtopic dermatitis (AD) (or atopic eczema) is a chronic inflammatory skin condition that a ects children and adults and has an important impact on quality of life. Topical corticosteroids (TCS) are the first-line therapy for this condition; however, they can be associated with significant adverse e ects when used chronically. Tacrolimus ointment (in its 2 manufactured strengths of 0.1% and 0.03%) might be an alternative treatment. Tacrolimus, together with pimecrolimus, are drugs called topical calcineurin inhibitors (TCIs). ObjectivesTo assess the e icacy and safety of topical tacrolimus for moderate and severe atopic dermatitis compared with other active treatments. Search methodsWe searched the following databases up to 3

Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.

No abstract